Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, published by WILEY, is a leading journal in the field of biomaterials and biomedical engineering, showcasing cutting-edge research that bridges the gap between material science and healthcare applications. With a robust 2023 impact factor reflecting its high-quality contributions, this journal is classified in the Q2 quartile for Biomaterials, Biomedical Engineering, and Ceramics and Composites, while achieving an impressive Q1 ranking in Metals and Alloys. The journal caters to a diverse readership, including researchers, professionals, and students, aiming to facilitate innovation and advancements in biocompatible materials and their applications in medical devices and tissue engineering. Access options for readers are available, ensuring the latest studies and findings are readily accessible to all stakeholders in this dynamic field. As it progresses towards its 2024 target, the JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A continues to be an essential resource for anyone involved in the development and application of biomedical materials.

Progress in Biomaterials is a premier journal published by Springer Heidelberg, dedicated to advancing the field of biomaterials through the dissemination of high-quality research articles, reviews, and case studies. The journal, with an ISSN of 2194-0509 and an E-ISSN of 2194-0517, holds an esteemed position within both the Biomaterials and Chemical Engineering fields, as evidenced by its rankings in the Q2 and Q1 quartiles, respectively. With its convergence over the years from 2013 to 2023, it has maintained a strong impact on scientific discourse, ranking #15 in Chemical Engineering and #30 in Biomaterials according to Scopus metrics. The journal is based in Heidelberg, Germany, and aims to provide an open platform for interdisciplinary collaboration amongst researchers, professionals, and students alike, fostering innovation and progress in biomaterials research. As a crucial resource for those engaged in this dynamic field, it empowers authors and readers to explore the latest trends, technologies, and applications in biomaterials development.

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

Biomaterials Research, published by the American Association for the Advancement of Science, is a prominent open access journal established in 2014, dedicated to advancing the field of biomaterials. Based in the United Kingdom, this journal has swiftly become an essential platform for researchers and practitioners, offering groundbreaking insights in biomaterials, biomedical engineering, ceramics and composites, and miscellaneous medical fields. With its impressive Q1 ranking across multiple relevant categories in 2023 and its strong Scopus rankings, including a remarkable 90th percentile in the medicine category, Biomaterials Research showcases high-quality, peer-reviewed research designed to address both practical and theoretical challenges in biomaterials science. As an open access journal, it promotes wider dissemination and accessibility of research findings, crucial for fostering innovation and collaboration within the scientific community. Researchers, professionals, and students alike are encouraged to contribute, read, and engage with the latest developments in this dynamic field.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

JOURNAL OF NANOBIOTECHNOLOGY is a distinguished academic journal published by BMC in the field of nanobiotechnology, focusing on the intersection of nanoscience, biotechnology, and biomedical engineering. Since its inception in 2003, this open-access journal has played a pivotal role in disseminating high-quality research, becoming a leading platform for innovators and scholars alike. With a remarkable impact factor and consistently ranking in the Q1 category across multiple fields—including Applied Microbiology, Bioengineering, and Pharmaceutical Science—the journal demonstrates its critical relevance and influence in advancing knowledge and applications in nanobiotechnology. Furthermore, its impressive Scopus rankings reflect its commitment to rigorously peer-reviewed content, making it a go-to resource for researchers, professionals, and students striving to push the boundaries of science. Given its broad scope, covering emerging trends and technologies, JOURNAL OF NANOBIOTECHNOLOGY continues to foster collaboration and innovation across multidisciplinary fields, inviting submissions from across the globe.